Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Key TakeawaysJefferies initiated a "buy" rating on Rocket Pharmaceuticals based on the biotech firm's experimental gene therapies.Jefferies also set a price target of $29.The analysts said they were especially optimistic about Rocket's treatment for a rare genetic heart condition, which they believe could be a$1 billion opportunity for the company. Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism ab ...